Arcus Biosciences, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Regular earnings reports show if the company is making money and growing its business.
Director elections and auditor approval affect who oversees the company's finances and decisions.
Failed drug trials mean less chance of future revenue and show research risks.
Lost partnership options mean fewer revenue opportunities from Gilead collaboration.
Regular earnings reports show if the company is making money and growing its business.
Leadership changes can affect company strategy and operations.
Stocky reads Arcus Biosciences, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Arcus Biosciences, Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Q2 2026 financial results announced for six months ended June 30.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.